Use of N-acetylneuraminic acid aldolase in catalytic synthesis of N-acetylneuraminic acid

US9512420B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9512420-B2
Application numberUS-201314396317-A
CountryUS
Kind codeB2
Filing dateNov 27, 2013
Priority dateOct 16, 2013
Publication dateDec 6, 2016
Grant dateDec 6, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

It discloses a use of N-acetylneuraminic acid aldolase with an amino acid sequence as shown in SEQ ID NO: 2 in catalytic synthesis of N-acetylneuraminic acid. The preparation of N-acetylneuraminic acid is to use the N-acetylneuraminic acid aldolase with the amino acid sequence as shown in SEQ ID NO: 2 as a catalyst, and N-acetylmannosamine and pyruvic acid as substrates.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for using Corynebacterium N-acetylneuraminic acid aldolase for preparing N-acetylneuraminic acid with N-acetylmannosamine and pyruvic acid in a buffer. 2. The method according to claim 1 , wherein the concentration of N-acetylneuraminic acid aldolase is from 0.36 to 300 U·mL −1 , the concentration of N-acetylmannosamine is from 100 to 1000 mmol·L −1 and the concentration of pyruvic acid is from 100 to 2000 mmol·L −1 ; a reaction temperature is between 25 and 60° C.; and a reaction time is between 0.1 and 12 hours. 3. The method according to claim 1 , wherein the buffer is a Tris-HCl buffer at pH between 7 and 8.8, or a glycine-NaOH buffer at pH between 9.0 and 9.5. 4. The method according to claim 1 , wherein the N-acetylneuraminic acid aldolase is produced by E. coli that is transformed by an expression vector that contains N-acetylneuraminic acid aldolase cDNA having the nucleic acid sequence as shown in SEQ ID NO: 1. 5. The method according to claim 4 , the expression vector is a pET-28a vector.

Assignees

Inventors

Classifications

  • N-Acetylneuraminate lyase (4.1.3.3) · CPC title

  • using catalysts, e.g. selective catalysts · CPC title

  • Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

  • C12N9/88Primary

    Lyases (4.) · CPC title

  • Preparation of nitrogen-containing carbohydrates · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9512420B2 cover?
It discloses a use of N-acetylneuraminic acid aldolase with an amino acid sequence as shown in SEQ ID NO: 2 in catalytic synthesis of N-acetylneuraminic acid. The preparation of N-acetylneuraminic acid is to use the N-acetylneuraminic acid aldolase with the amino acid sequence as shown in SEQ ID NO: 2 as a catalyst, and N-acetylmannosamine and pyruvic acid as substrates.
Who is the assignee on this patent?
Nanjing Univ Of Tech, Nanjing University Of Technology
What technology area does this patent fall under?
Primary CPC classification C12N9/88. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).